Real-world and trial data show ixekizumab and deucravacitinib provide durable efficacy in psoriatic arthritis. Ixekizumab achieved high remission rates and drug retention over 24 months, while deucravacitinib improved outcomes across multiple disease domains in the phase III POETYK PsA-2 trial.
Clarity Pharmaceuticals announced preliminary SECuRE trial results showing 74% of participants achieved PSA25 and 81% disease control with 8 GBq 67Cu-SAR-bisPSMA. A 76-year-old patient achieved undetectable disease after two cycles, and shares rose 14%.
Phase 3 PROTEUS: perioperative apalutamide plus ADT met both dual primary endpoints in high-risk localized prostate cancer, raising pCR/MRD rates to 8.9% vs 1.0% and cutting metastasis or death risk by 20%.
Eli Lilly's Taltz-Zepbound combination achieved significant improvements in two Phase 3b trials for plaque psoriasis and psoriatic arthritis with obesity. Combo therapy led to complete skin clearance and weight loss in psoriasis, and rapid disease activity reduction in psoriatic arthritis. The results were presented at AAD 2026.
PCF invests $6.3M in 31 Young Investigator Awards, supports Creativity Awards, and hosts Home Run Challenge 2026 to raise awareness. The foundation has contributed to 15 FDA-approved therapies over its 30-year history.
Recent prostate cancer research includes a Phase 2 trial of opaganib in advanced disease, a SEER study linking older age to higher mortality in bone-only metastases, and AI and genetic tools that improve detection.
European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.
Novartis reported Phase III PSMAddition data showing Pluvicto plus standard of care cut the risk of PSA progression by 58% in PSMA-positive metastatic hormone-sensitive prostate cancer. Regulatory decisions in the United States, China and Japan are expected in the second half of 2026.
A post hoc STAMPEDE analysis found lower on-treatment PSA levels were strongly associated with improved long-term survival in advanced prostate cancer, but disease burden still affected outcomes.
PSMA-PET imaging leads to earlier use of advanced therapies like ARPIs in prostate cancer patients compared to bone scans. Real-world data on 177Lu-PSMA-617 shows comparable efficacy to the VISION trial in mCRPC patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07684781 |
Effectiveness of Electroacupuncture at Xuanzhong (GB39) and Tongli (HT5) Points in Post-Stroke Aphasia |
NOT_YET_RECRUITING | NA |
| NCT07516223 |
MRI-Assisted Guidance for Non-Essential Tissue Sampling |
RECRUITING | NA |
| NCT06872619 |
RegisterPROS - A Registry for Prostate Cancers |
ENROLLING_BY_INVITATION | |
| NCT05732441 |
Therapeutic Study of Prostatitis With Elevated PSA |
UNKNOWN | NA |
| NCT05629494 |
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test |
RECRUITING | PHASE4 |
| NCT05306314 |
Retrospective Chart Review of Treataprost Added to Antibiotic Treatment in Patients With Chronic Prostatitis |
UNKNOWN | |
| NCT04782713 |
Smart Prostate Specific Antigen (PSA) Screening Study |
COMPLETED | NA |
| NCT04393376 |
PSA Glycomics Assay for Early Detection of Prostate Cancer |
UNKNOWN | NA |
| NCT04319783 |
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04251546 |
Prediction Model fo Screening and Diagnosis of Prostate Cancer in PSA Gray Zone Based on Serum PHI Combined With TPV |
UNKNOWN |
